<DOC>
	<DOCNO>NCT00359905</DOCNO>
	<brief_summary>A new drug treatment benign prostatic hyperplasia compare placebo tamsulosin ( drug belong therapeutic class ) determine safe effective ( first phase study last approximately 18 week ) use another 9 month determine long-term safety .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Silodosin Treatment Signs Symptoms BPH</brief_title>
	<detailed_description>This multi-centre , double-blind , placebo active control , parallel 12 week treatment trial men sign symptom benign prostatic hyperplasia , follow 9 month open-label phase . The following procedure use : physical exam , electrocardiogram , clinical laboratory test , vital sign , International Prostate Symptom Score , maximum urine flow rate , adverse event , concomitant medication , quality life compliance . 93 centre 11 European country ( Finland , France , Germany , Italy , Netherlands , Poland , Romania , Russia , Spain , Ukraine , UK ) involve</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<criteria>Males good general health least 50 year age , symptom moderate severe Benign Prostatic Hyperplasia Medical condition would confound efficacy evaluation Medical condition would unsafe use alphablocker Use concomitant drug would confound efficacy evaluation Use concomitant drug would unsafe alphablocker</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>alpha-blocker</keyword>
</DOC>